Dresden

• TYPER Recruiting
  2024-520290-12-00 6 2025-11-04 Hormone receptor–positive (HRpos)/human epidermal growth factor recept
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P … Recruiting
  2024-517131-52-00 5 2025-11-03 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
• Effect of TRI-001 in patients with chronic limb threatening ischemia Recruiting
  2024-517765-16-00 7 2025-11-01 Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripher
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder … Recruiting
  2023-506296-97-00 5 2025-10-28 Moderate to Severe Plaque Psoriasis
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting
  2024-519081-49-00 4 2025-10-28 Moderate to severe atopic dermatitis
• INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complica … Recruiting
  2025-521048-39-00 5 2025-10-28 Parkinson Disease
• Phase I/IIa study to test the safety and efficacy of MSC from umbilical cord tissue (UC-MSC) for the treatment of cartilage damage in the kn … Recruiting
  2024-517684-23-00 7 2025-10-23 Cartilage defect of the knee joint
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid … Recruiting
  2025-520564-17-00 5 2025-10-16 Hidradenitis suppurativa (HS)
• A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell … Recruiting
  2024-516234-35-00 9 2025-10-15 Relapsed or Refractory B-Cell Malignancies
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• Randomized phase III trial of sequential Re-Radiochemotherapy and Pembrolizumab versus Immuno(chemo)therapy for locoregionally recurrent PD- … Recruiting
  2024-520264-33-00 5 2025-10-07 Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
• Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting
  2024-517632-22-00 5 2025-10-06 Hidradenitis Suppurativa
• A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Recruiting
  2024-519736-17-00 4 2025-10-03 Hidradenitis Suppurativa
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting
  2023-509121-51-00 5 2025-09-30 Moderate-to-Severe Atopic Dermatitis
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti … Recruiting
  2024-517745-14-00 4 2025-09-24 Multiple Sclerosis Spasticity
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting
  2025-520672-26-00 9 2025-09-16 Gastrointestinal Neoplasms
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer

Showing 241–264 of 943 trials